At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
sunitinib malate +1 moredrug
Likely dose
sunitinib malate 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Sunitinib Malate in Patients With Renal Cell Carcinoma and Unresectable Primary Tumors
In Brief
A Phase 2 clinical trial evaluating sunitinib malate and conventional surgery for Kidney Cancer. Completed, enrolled 30 participants across 1 site.
Detailed Summary
RATIONALE: Sunitinib may stop the growth of kidney cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well sunitinib works in treating patients with kidney cancer that cannot be removed by surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2007
Primary CompletionMar 2011
Study CompletionSep 2013
TodayJul 2026
First PostedApr 13, 2007
Enrollment StartMar 1, 2007
Primary CompletionMar 1, 2011
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 19.2 years ago
Interventions
sunitinib malatedrug
Sunitinib will be dosed at 50 mg p.o. daily
conventional surgeryprocedure
nephrectomy